Jose Juan Illarramendi
Overview
Explore the profile of Jose Juan Illarramendi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arraras J, Illarramendi J, Manterola A, Zarandona U, Ibanez B, Bottomley A, et al.
Contemp Oncol (Pozn)
. 2025 Feb;
28(4):350-357.
PMID: 39935753
Introduction: Metastatic breast cancer (MBC) can profoundly impact patients' lives. The health-related quality of life (HRQOL) of MBC metavivors remains a paramount concern. This study exa-mined the multifaceted aspects of...
2.
Arraras J, Illarramendi J, Manterola A, de la Cruz S, Zarandona U, Ibanez B, et al.
Menopause
. 2023 Apr;
30(6):613-620.
PMID: 37022296
Objective: In this article, the quality of life (QOL) of Spanish postmenopausal early-stage breast cancer patients who have finished endocrine therapy (ET), QOL changes after endocrine therapy cessation, and the...
3.
Arraras J, Illarramendi J, Manterola A, de la Cruz S, Zarandona U, Ibanez B, et al.
Psychooncology
. 2023 Mar;
32(5):730-740.
PMID: 36882856
Objectives: To describe the Quality of Life (QOL) of breast-cancer patients diagnosed with COVID-19 and analyse its evolution, compare the QOL of these patients according to the COVID-19 wave in...
4.
Arraras J, Nolte S, Liegl G, Rose M, Manterola A, Illarramendi J, et al.
Health Qual Life Outcomes
. 2021 Aug;
19(1):208.
PMID: 34461909
Purpose: General population normative data for the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire facilitates interpretation of data assessed from cancer patients. This study aims to...
5.
Lopez-Vega J, Alvarez I, Anton A, Illarramendi J, Llombart A, Boni V, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298725
This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with...
6.
Illarramendi J, Arraras J, Zarandona U
Psychooncology
. 2020 Jul;
29(9):1416-1417.
PMID: 32648621
No abstract available.
7.
Ciruelos E, Diaz M, Isla M, Lopez R, Bernabe R, Gonzalez E, et al.
Eur J Cancer Care (Engl)
. 2019 Oct;
28(6):e13164.
PMID: 31571304
Objectives: Although new therapies against metastatic cancer have been developed in recent decades, chemotherapy is still an important treatment option. Prolonged treatment and side-effects are often discouraging for patients, and...
8.
Arraras J, Asin G, Illarramendi J, Manterola A, Salgado E, Dominguez M
Rev Esp Geriatr Gerontol
. 2019 Jul;
54(6):321-328.
PMID: 31266659
Background And Objectives: Quality of life (QoL) is a key outcome for elderly cancer patients. The EORTC has developed QLQ-ELD14, a questionnaire that assesses important age-specific issues for older patients...
9.
Sanchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martinez-Janez N, Martinez-de-Duenas E, et al.
J Drug Assess
. 2019 May;
8(1):62-69.
PMID: 31069129
The aim of this survey conducted by 20 leading Spanish oncologists was to analyze the concurrence between Spanish clinical practice and the recently published definition of the optimal sequence for...
10.
Ortega V, Anton A, Garau I, Afonso N, Calvo L, Fernandez Y, et al.
Clin Breast Cancer
. 2019 Jan;
19(2):105-112.
PMID: 30679100
Background: Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the...